http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Jul 2026 16:05:11 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Keros+Therapeutics+CFO+resigns%2C+interim+finance+chief+named/26801588.html <p>Keros Therapeutics (NASDAQ: KROS) announced that Keith Regnante resigned as Chief Financial Officer, effective August 3, 2026, to pursue other opportunities. The company stated his departure was voluntary and not the result of any disagreement over accounting practices, financial statements, internal controls, or company policies.</p><p>The company's Board of Directors appointed Annita Tanini, previously Corporate Controller and Vice President of Finance, as interim principal financial officer and principal accounting officer, effective August 4, 2026. Keros Therapeutics said it has begun a search for a permanent CFO.</p><p>Tanini, 55, has held finance leadership roles at the company since May 2019. She previously served http://www.streetinsider.com/Corporate+News/Keros+Therapeutics+CFO+resigns%2C+interim+finance+chief+named/26801588.html Wed, 22 Jul 2026 16:05:11 -0400 KROS http://www.streetinsider.com/Management+Changes/Keros+Therapeutics+CFO+resigns%2C+interim+finance+chief+named/26801588.html <p>Keros Therapeutics (NASDAQ: KROS) announced that Keith Regnante resigned as Chief Financial Officer, effective August 3, 2026, to pursue other opportunities. The company stated his departure was voluntary and not the result of any disagreement over accounting practices, financial statements, internal controls, or company policies.</p><p>The company's Board of Directors appointed Annita Tanini, previously Corporate Controller and Vice President of Finance, as interim principal financial officer and principal accounting officer, effective August 4, 2026. Keros Therapeutics said it has begun a search for a permanent CFO.</p><p>Tanini, 55, has held finance leadership roles at the company since May 2019. She previously served http://www.streetinsider.com/Management+Changes/Keros+Therapeutics+CFO+resigns%2C+interim+finance+chief+named/26801588.html Wed, 22 Jul 2026 16:05:11 -0400 KROS http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+17/26801505.html si-local-file:///var/storage/secattach/20260722/26801505.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+17/26801505.html Wed, 22 Jul 2026 16:01:00 -0400 KROS O.47503207 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+17/26801505.html si-local-file:///var/storage/secattach/20260722/26801505.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+17/26801505.html Wed, 22 Jul 2026 16:01:00 -0400 KROS O.47503207 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+15++Filed+by%3A+BIENAIME+JEAN+JACQUES/26784428.html si-local-file:///var/storage/secattach/20260717/26784428.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+15++Filed+by%3A+BIENAIME+JEAN+JACQUES/26784428.html Fri, 17 Jul 2026 16:10:00 -0400 KROS O.47503207 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+15++Filed+by%3A+BIENAIME+JEAN+JACQUES/26784428.html si-local-file:///var/storage/secattach/20260717/26784428.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+15++Filed+by%3A+BIENAIME+JEAN+JACQUES/26784428.html Fri, 17 Jul 2026 16:10:00 -0400 KROS O.47503207 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Keros+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+BlackRock+Portfolio+Management+LLC/26783098.html si-local-file:///var/storage/secattach/20260717/26783098.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Keros+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+BlackRock+Portfolio+Management+LLC/26783098.html Fri, 17 Jul 2026 11:34:00 -0400 KROS O.47503207 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Keros+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+BlackRock+Portfolio+Management+LLC/26783098.html si-local-file:///var/storage/secattach/20260717/26783098.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Keros+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+BlackRock+Portfolio+Management+LLC/26783098.html Fri, 17 Jul 2026 11:34:00 -0400 KROS O.47503207 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+01++Filed+by%3A+Prener+Anne/26736017.html si-local-file:///var/storage/secattach/20260706/26736017.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+01++Filed+by%3A+Prener+Anne/26736017.html Mon, 06 Jul 2026 16:31:00 -0400 KROS O.47503207 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+01++Filed+by%3A+Prener+Anne/26736017.html si-local-file:///var/storage/secattach/20260706/26736017.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+01++Filed+by%3A+Prener+Anne/26736017.html Mon, 06 Jul 2026 16:31:00 -0400 KROS O.47503207 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+01++Filed+by%3A+Prener+Anne/26735892.html si-local-file:///var/storage/secattach/20260706/26735892.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+01++Filed+by%3A+Prener+Anne/26735892.html Mon, 06 Jul 2026 16:27:00 -0400 KROS O.47503207 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+01++Filed+by%3A+Prener+Anne/26735892.html si-local-file:///var/storage/secattach/20260706/26735892.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jul+01++Filed+by%3A+Prener+Anne/26735892.html Mon, 06 Jul 2026 16:27:00 -0400 KROS O.47503207 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jun+23/26692226.html si-local-file:///var/storage/secattach/20260625/26692226.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jun+23/26692226.html Thu, 25 Jun 2026 16:02:00 -0400 KROS O.47503207 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jun+23/26692226.html si-local-file:///var/storage/secattach/20260625/26692226.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Keros+Therapeutics%2C+Inc.++For%3A+Jun+23/26692226.html Thu, 25 Jun 2026 16:02:00 -0400 KROS O.47503207 http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html <p>Keros Therapeutics, Inc. (Nasdaq: KROS) announced the appointment of Anne Prener, M.D., Ph.D., to its board of directors, effective July 1, 2026.</p> <p>Prener currently serves as a senior innovation advisor at the University of Copenhagen and as a non-executive director at XSpray Pharma. She previously served as chief executive officer of Imbria Pharmaceuticals Inc. from July 2020 to September 2024, and as venture partner at SV Health Investors from September 2020 to October 2024.</p> <p>Earlier roles include chief executive officer of Freeline Therapeutics Ltd. from July 2017 to June 2019, and chief executive officer of Gyroscope Therapeutics Ltd. from August 2016 to http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html Thu, 25 Jun 2026 16:01:16 -0400 A.02973684 A.22764036 A.23559738 A.34737659 A.50114092 A.60012013 KROS O.00285735 O.01656696 O.16456473 O.22666045 O.23618244 O.28675197 O.47503207 http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html <p>Keros Therapeutics, Inc. (Nasdaq: KROS) announced the appointment of Anne Prener, M.D., Ph.D., to its board of directors, effective July 1, 2026.</p> <p>Prener currently serves as a senior innovation advisor at the University of Copenhagen and as a non-executive director at XSpray Pharma. She previously served as chief executive officer of Imbria Pharmaceuticals Inc. from July 2020 to September 2024, and as venture partner at SV Health Investors from September 2020 to October 2024.</p> <p>Earlier roles include chief executive officer of Freeline Therapeutics Ltd. from July 2017 to June 2019, and chief executive officer of Gyroscope Therapeutics Ltd. from August 2016 to http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html Thu, 25 Jun 2026 16:01:16 -0400 A.02973684 A.22764036 A.23559738 A.34737659 A.50114092 A.60012013 KROS O.00285735 O.01656696 O.16456473 O.22666045 O.23618244 O.28675197 O.47503207 http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html <p>Keros Therapeutics, Inc. (Nasdaq: KROS) announced the appointment of Anne Prener, M.D., Ph.D., to its board of directors, effective July 1, 2026.</p> <p>Prener currently serves as a senior innovation advisor at the University of Copenhagen and as a non-executive director at XSpray Pharma. She previously served as chief executive officer of Imbria Pharmaceuticals Inc. from July 2020 to September 2024, and as venture partner at SV Health Investors from September 2020 to October 2024.</p> <p>Earlier roles include chief executive officer of Freeline Therapeutics Ltd. from July 2017 to June 2019, and chief executive officer of Gyroscope Therapeutics Ltd. from August 2016 to http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html Thu, 25 Jun 2026 16:01:16 -0400 A.02973684 A.22764036 A.23559738 A.34737659 A.50114092 A.60012013 KROS O.00285735 O.01656696 O.16456473 O.22666045 O.23618244 O.28675197 O.47503207 http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html <p>Keros Therapeutics, Inc. (Nasdaq: KROS) announced the appointment of Anne Prener, M.D., Ph.D., to its board of directors, effective July 1, 2026.</p> <p>Prener currently serves as a senior innovation advisor at the University of Copenhagen and as a non-executive director at XSpray Pharma. She previously served as chief executive officer of Imbria Pharmaceuticals Inc. from July 2020 to September 2024, and as venture partner at SV Health Investors from September 2020 to October 2024.</p> <p>Earlier roles include chief executive officer of Freeline Therapeutics Ltd. from July 2017 to June 2019, and chief executive officer of Gyroscope Therapeutics Ltd. from August 2016 to http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html Thu, 25 Jun 2026 16:01:16 -0400 A.02973684 A.22764036 A.23559738 A.34737659 A.50114092 A.60012013 KROS O.00285735 O.01656696 O.16456473 O.22666045 O.23618244 O.28675197 O.47503207 http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html <p>Keros Therapeutics, Inc. (Nasdaq: KROS) announced the appointment of Anne Prener, M.D., Ph.D., to its board of directors, effective July 1, 2026.</p> <p>Prener currently serves as a senior innovation advisor at the University of Copenhagen and as a non-executive director at XSpray Pharma. She previously served as chief executive officer of Imbria Pharmaceuticals Inc. from July 2020 to September 2024, and as venture partner at SV Health Investors from September 2020 to October 2024.</p> <p>Earlier roles include chief executive officer of Freeline Therapeutics Ltd. from July 2017 to June 2019, and chief executive officer of Gyroscope Therapeutics Ltd. from August 2016 to http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html Thu, 25 Jun 2026 16:01:16 -0400 A.02973684 A.22764036 A.23559738 A.34737659 A.50114092 A.60012013 KROS O.00285735 O.01656696 O.16456473 O.22666045 O.23618244 O.28675197 O.47503207 http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html <p>Keros Therapeutics, Inc. (Nasdaq: KROS) announced the appointment of Anne Prener, M.D., Ph.D., to its board of directors, effective July 1, 2026.</p> <p>Prener currently serves as a senior innovation advisor at the University of Copenhagen and as a non-executive director at XSpray Pharma. She previously served as chief executive officer of Imbria Pharmaceuticals Inc. from July 2020 to September 2024, and as venture partner at SV Health Investors from September 2020 to October 2024.</p> <p>Earlier roles include chief executive officer of Freeline Therapeutics Ltd. from July 2017 to June 2019, and chief executive officer of Gyroscope Therapeutics Ltd. from August 2016 to http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html Thu, 25 Jun 2026 16:01:16 -0400 A.02973684 A.22764036 A.23559738 A.34737659 A.50114092 A.60012013 KROS O.00285735 O.01656696 O.16456473 O.22666045 O.23618244 O.28675197 O.47503207 http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html <p>Keros Therapeutics, Inc. (Nasdaq: KROS) announced the appointment of Anne Prener, M.D., Ph.D., to its board of directors, effective July 1, 2026.</p> <p>Prener currently serves as a senior innovation advisor at the University of Copenhagen and as a non-executive director at XSpray Pharma. She previously served as chief executive officer of Imbria Pharmaceuticals Inc. from July 2020 to September 2024, and as venture partner at SV Health Investors from September 2020 to October 2024.</p> <p>Earlier roles include chief executive officer of Freeline Therapeutics Ltd. from July 2017 to June 2019, and chief executive officer of Gyroscope Therapeutics Ltd. from August 2016 to http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html Thu, 25 Jun 2026 16:01:16 -0400 A.02973684 A.22764036 A.23559738 A.34737659 A.50114092 A.60012013 KROS O.00285735 O.01656696 O.16456473 O.22666045 O.23618244 O.28675197 O.47503207 http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html <p>Keros Therapeutics, Inc. (Nasdaq: KROS) announced the appointment of Anne Prener, M.D., Ph.D., to its board of directors, effective July 1, 2026.</p> <p>Prener currently serves as a senior innovation advisor at the University of Copenhagen and as a non-executive director at XSpray Pharma. She previously served as chief executive officer of Imbria Pharmaceuticals Inc. from July 2020 to September 2024, and as venture partner at SV Health Investors from September 2020 to October 2024.</p> <p>Earlier roles include chief executive officer of Freeline Therapeutics Ltd. from July 2017 to June 2019, and chief executive officer of Gyroscope Therapeutics Ltd. from August 2016 to http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html Thu, 25 Jun 2026 16:01:16 -0400 A.02973684 A.22764036 A.23559738 A.34737659 A.50114092 A.60012013 KROS O.00285735 O.01656696 O.16456473 O.22666045 O.23618244 O.28675197 O.47503207 http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html <p>Keros Therapeutics, Inc. (Nasdaq: KROS) announced the appointment of Anne Prener, M.D., Ph.D., to its board of directors, effective July 1, 2026.</p> <p>Prener currently serves as a senior innovation advisor at the University of Copenhagen and as a non-executive director at XSpray Pharma. She previously served as chief executive officer of Imbria Pharmaceuticals Inc. from July 2020 to September 2024, and as venture partner at SV Health Investors from September 2020 to October 2024.</p> <p>Earlier roles include chief executive officer of Freeline Therapeutics Ltd. from July 2017 to June 2019, and chief executive officer of Gyroscope Therapeutics Ltd. from August 2016 to http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html Thu, 25 Jun 2026 16:01:16 -0400 A.02973684 A.22764036 A.23559738 A.34737659 A.50114092 A.60012013 KROS O.00285735 O.01656696 O.16456473 O.22666045 O.23618244 O.28675197 O.47503207 http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html <p>Keros Therapeutics, Inc. (Nasdaq: KROS) announced the appointment of Anne Prener, M.D., Ph.D., to its board of directors, effective July 1, 2026.</p> <p>Prener currently serves as a senior innovation advisor at the University of Copenhagen and as a non-executive director at XSpray Pharma. She previously served as chief executive officer of Imbria Pharmaceuticals Inc. from July 2020 to September 2024, and as venture partner at SV Health Investors from September 2020 to October 2024.</p> <p>Earlier roles include chief executive officer of Freeline Therapeutics Ltd. from July 2017 to June 2019, and chief executive officer of Gyroscope Therapeutics Ltd. from August 2016 to http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html Thu, 25 Jun 2026 16:01:16 -0400 A.02973684 A.22764036 A.23559738 A.34737659 A.50114092 A.60012013 KROS O.00285735 O.01656696 O.16456473 O.22666045 O.23618244 O.28675197 O.47503207 http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html <p>Keros Therapeutics, Inc. (Nasdaq: KROS) announced the appointment of Anne Prener, M.D., Ph.D., to its board of directors, effective July 1, 2026.</p> <p>Prener currently serves as a senior innovation advisor at the University of Copenhagen and as a non-executive director at XSpray Pharma. She previously served as chief executive officer of Imbria Pharmaceuticals Inc. from July 2020 to September 2024, and as venture partner at SV Health Investors from September 2020 to October 2024.</p> <p>Earlier roles include chief executive officer of Freeline Therapeutics Ltd. from July 2017 to June 2019, and chief executive officer of Gyroscope Therapeutics Ltd. from August 2016 to http://www.streetinsider.com/Board+Changes/Keros+Therapeutics+names+Anne+Prener+to+its+board+of+directors/26692192.html Thu, 25 Jun 2026 16:01:16 -0400 A.02973684 A.22764036 A.23559738 A.34737659 A.50114092 A.60012013 KROS O.00285735 O.01656696 O.16456473 O.22666045 O.23618244 O.28675197 O.47503207